Sells research instruments, reagents and software, plus diagnostic instruments and consumables, to drug developers, research institutions and diagnostic laboratories.
10-K for FY2025, filed Feb 24, 2026Our comprehensive portfolio of technologies helps life sciences researchers better understand diseases and develop treatments. We provide a…View ↗
The Life Sciences segment principally generates revenue from sales of instruments, reagents, software, subscriptions, detection and imaging…View ↗
Our customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health…View ↗
Most revenue comes from products: customers pay for instruments, reagents and certain software when delivered. Service revenue generally comes in over the service or contract period.
10-K for FY2025, filed Feb 24, 2026The revenue generated from the sale of instruments, reagents, and certain software is recognized at a point in time. The Company recognizes…View ↗
The revenue generated from the sale of licenses for software as a service, cloud services, subscriptions, and laboratory services and…View ↗
Product revenue is recognized at a point in time and service revenue is generally recognized over time.View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$2.9B
10-K for FY2025, filed Feb 24, 2026
$2.9B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
84%
FY2022: 80%
|
Product, FY2025
$2.4B Sources
|
Sold outright |
|
Service
Recurring
10-K for FY2025, filed Feb 24, 2026 |
16%
FY2022: 20%
|
Service, FY2025
$466.1M Sources
|
Recurring |
Drug developers and research institutions, diagnostic laboratories, and healthcare organizations buy products and services. Revvity sells mainly through its own sales force and uses distributors where it has no direct sales presence.
10-K for FY2025, filed Feb 24, 2026Our comprehensive portfolio of technologies helps life sciences researchers better understand diseases and develop treatments. We provide a…View ↗
All of our businesses market their products and services primarily through their own specialized sales forces. As of December 28, 2025, we…View ↗
Our customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health…View ↗
The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to…View ↗
Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 10, 2026
$62.3MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 3, 2026
As a reminder, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China (“China IDX”), which…View ↗
Shrinking. Revenue fell 25% in 4 years, from $3.8B in FY2022 to $2.9B in FY2025, about 7% a year.
Applied markets exit
The older report included environmental, food and industrial analytical products and services within Discovery & Analytical Solutions and described a planned sale of certain businesses. The latest report describes Life Sciences and Diagnostics segments instead.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 24, 2026In August 2022, we entered into a Master Purchase and Sale Agreement (the “Purchase Agreement”) with Polaris Purchaser, L.P. (the…View ↗
The applied markets consist of environmental, food and industrial markets.View ↗
For the environmental market, we develop and provide analytical technologies, solutions and services that enable our customers to…View ↗
We also offer a variety of solutions that help farmers and food producers provide a growing population with food that is safe, nutritious…View ↗
We also provide analytical instrumentation for industrial markets, which include the chemical, semiconductor, mining, energy, lubricant…View ↗
We report our business in two segments: Life Sciences and Diagnostics.View ↗
Loading...